Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning.
'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.'
As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market.
Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients.
'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.'
About Ibogaine by David Dardashti:
Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Pulmatrix (PULM) Q2 Revenue Falls 100%
Key Points GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a substantial reduction in R&D activity. Pulmatrix focused on finalizing its merger with Cullgen and pursuing asset divestitures; no forward financial guidance was provided. These 10 stocks could mint the next wave of millionaires › Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025. Net loss per share (GAAP) was $(0.42), compared to $(1.59) in Q2 2024. There were no Wall Street analyst estimates available this quarter, but the reported GAAP loss per share of $(0.42) represented a substantial narrowing from last year's GAAP result of $(1.59) in Q2 2024, mainly due to a near-total reduction in research and development spending. The quarter highlights Pulmatrix's strategic pivot: winding down its prior clinical business, trimming operational costs, conserving cash, and focusing on completing its merger with Cullgen. The company offered no forward guidance for upcoming quarters as it transitions operations. Business Overview and Recent Areas of Focus Pulmatrix's core business has centered on developing inhaled therapies using its proprietary iSPERSE™ technology—a dry powder drug delivery platform aimed at improving medication delivery to the lungs. This platform was designed to increase efficiency and tolerability in treatments compared to traditional inhalers or oral medications, positioning the company in the respiratory therapeutics space. Over the past year, Pulmatrix's strategic priorities have shifted dramatically. It has halted most clinical operations, halted R&D spending, and now seeks to divest its iSPERSE™ intellectual property and remaining clinical assets. The company's ongoing viability depends on successfully completing its pending merger with Cullgen and monetizing its assets or securing royalty streams from former drug candidates such as PUR1900. Key success factors now rest less on product development and more on the execution of these strategic transactions. Quarter Highlights: Operations, Finances, and Pipeline Progress The quarter reflected a sharp operational downsizing as Pulmatrix's GAAP revenue dropped from $1.6 million in Q2 2024 to zero. This change resulted from the completion of the wind-down of its PUR1900 clinical trial. Former sources of operating income, such as milestone payments or funding for joint studies, concluded, and there were no new business or sales streams to replace them during the period. Research and development expense (GAAP) decreased from $2,834,000 in Q2 2024 to $14,000, a 99.5% drop. This near-total reduction in research spending came as Pulmatrix finished closing its flagship clinical programs and terminated related staff. The company stated: 'The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.' Helped by layoffs and cuts, although these savings were partially offset by legal and advisory expenses linked to the merger process. Net loss and operating loss (GAAP) both narrowed substantially. The reduced losses were primarily due to a sharp decrease in R&D expenses. Net loss (GAAP) dropped to $(1.55) million from $(5.81) million in Q2 2024. The company avoided any unusual charges this quarter, whereas the prior period had included a significant loss from an asset transaction with MannKind. With its extreme cost containment, Pulmatrix exited the quarter with a GAAP cash and cash equivalents position of $5.8 million (down from $9.5 million at December 31, 2024), which management expects will fund operations until the Cullgen merger is finalized. This period also saw Pulmatrix focus on two main strategic moves apart from operational cuts: the attempted sale of its iSPERSE™ intellectual property and clinical programs, and its merger with Cullgen. The company openly stated, 'Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.' These pipeline programs include PUR3100 for acute migraine (an orally inhaled dihydroergotamine engineered with iSPERSE™), PUR1800 for chronic obstructive pulmonary disease (a kinase inhibitor also using the iSPERSE™ platform), and PUR1900 (an inhaled formulation of an antifungal, developed with Cipla). Development or commercial responsibility for these candidates has ended or shifted to partners, and Pulmatrix itself has no ongoing clinical trials. Regulatory milestones from past years continued to carry some legacy value. For example, the Food and Drug Administration had accepted a Phase 2 study for PUR3100 and Pulmatrix's partner Cipla is moving forward with Phase 3 for PUR1900 in India. Pulmatrix may be eligible to receive a 2% royalty on possible future non-U.S. sales of PUR1900, but this would only occur if the product is successfully commercialized—a long-term and uncertain proposition. The most critical development during the second quarter was continued progress toward completing the merger with Cullgen, a protein degrader drug development company. Pulmatrix received stockholder approval and had its registration statement declared effective by the Securities and Exchange Commission. The merger remains contingent on regulatory approvals, including from the China Security Regulatory Commission and Nasdaq. Until the deal closes, Pulmatrix is in a holding pattern, and the company highlights that any delay or failure in closing poses significant risks to its ongoing viability. Looking Ahead: Guidance and Watchpoints Pulmatrix did not provide any financial guidance or operational outlook for the next quarter or upcoming year. No revenue or earnings forecast was offered by management in the latest earnings release. The company's leadership made clear that the near-term objective is to complete the planned merger and monetize or transfer its remaining assets. Because Pulmatrix is not currently developing or selling any medications, its short-term future is heavily dependent on successful asset divestitures and getting the Cullgen deal across the finish line. Investors and observers should monitor progress toward merger closing, potential updates on the sale of iSPERSE™-related patent portfolios, and any royalty developments with former pipeline candidates. PULM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CBC
3 hours ago
- CBC
RFK Jr.'s move to axe $500M in vaccine funding slammed
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has announced a $500-million cut to funding for mRNA vaccine development, insisting the technology used in COVID-19 vaccines poses risks. Many medical experts say the reasoning is untrue and could slow development of future vaccinations.
Globe and Mail
4 hours ago
- Globe and Mail
Pfizer Q2 2025 Earnings: Strong Growth Amid Challenges
Pfizer Inc ((PFE)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer's recent earnings call painted a picture of strong financial and operational performance in the second quarter of 2025. The company reported significant revenue growth, driven by key products and advancements in research and development. Despite these positive developments, Pfizer acknowledged challenges in certain product lines and potential impacts from ongoing policy discussions. The overall sentiment was optimistic, but tempered by uncertainties related to COVID-19 revenues and geopolitical factors. Record Revenue Growth Pfizer achieved a 10% operational increase in revenue for the second quarter of 2025, totaling $14.7 billion. This growth was fueled by the strong performance of key products such as Vyndaqel, Comirnaty, PAXLOVID, Padcev, and Eliquis, underscoring the company's successful commercial strategy and market leadership. Strong R&D Pipeline Progress The earnings call highlighted significant advancements in Pfizer's research and development pipeline. Promising developments in Elrexfio, Sigvotatug Vedotin, and Hympavzi were noted, indicating potential growth opportunities in the oncology and hematology markets. These advancements are expected to bolster Pfizer's future product offerings. Improved Financial Outlook Pfizer raised its full-year adjusted EPS guidance, reflecting strong year-to-date performance and favorable foreign exchange impacts. This improved financial outlook is a testament to the company's robust top-line performance and effective cost management strategies. Operational and Cost Efficiency The company reported an 8% operational decrease in total adjusted operating expenses, attributed to reduced marketing spend and pipeline optimization. These efficiencies have led to robust operating margins, enhancing Pfizer's overall financial health. Successful Commercial Strategy Pfizer maintained market leadership in key products like Eliquis and Vyndaqel, supported by strong international growth and effective engagement strategies. This successful commercial approach continues to drive the company's revenue growth and market presence. Challenges with IBRANCE and Seagen Products The earnings call acknowledged declines in IBRANCE and competitive pressures on Seagen products such as ADCETRIS and TUKYSA. These challenges have impacted growth in these segments, highlighting areas where Pfizer may need to focus on strategic improvements. Potential Policy and Tariff Impacts Ongoing discussions with the U.S. government regarding Most Favored Nation (MFN) policies and tariffs were mentioned as sources of uncertainty. These discussions could potentially impact Pfizer's future revenue and pricing strategies, adding a layer of complexity to the company's operational landscape. COVID-19 Revenue Uncertainty Despite a strong initial performance, Pfizer expressed uncertainty regarding COVID-19 vaccine and treatment revenues for the second half of the year. This uncertainty has led to a derisking of guidance, reflecting the unpredictable nature of the pandemic's impact on the company's financials. Forward-Looking Guidance Pfizer's forward-looking guidance included an increase in its adjusted diluted EPS guidance for the full year, driven by strong year-to-date performance. The company reported a 10% operational revenue increase to $14.7 billion and adjusted diluted earnings per share of $0.78, surpassing expectations. Pfizer emphasized its strategic priorities, including expanding its R&D portfolio and leveraging technological advancements to enhance margins and productivity gains, positioning the company for continued growth. In conclusion, Pfizer's earnings call reflected a strong financial performance in the second quarter of 2025, with significant revenue growth and advancements in R&D. While the overall sentiment was positive, challenges remain in certain product lines and potential policy impacts. The company's forward-looking guidance suggests continued growth, supported by strategic priorities and operational efficiencies.
